Loading
Life sciences · Journal article
Discover Oncology · September 18, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
To describe a potential first case of carboplatin-induced macular toxicity occurring during systemic treatment for metastatic non–small cell lung cancer (NSCLC). Retrospective case report with a literature review. A 48-year-old man developed bilateral vision loss three days after receiving first two cycles of chemoimmunotherapy consisting of carboplatin (400mg/m 2 ), pemetrexed (500mg/m 2 ), and pembrolizumab (200 mg) administered intravenously every four weeks. Clinical evaluation revealed rapidly progressive bilateral visual decline with a central scotoma. Multimodal imaging demonstrated foveal hyper-autofluorescence and disruption of the foveal ellipsoid zone in both eyes. Electrophysiological testing showed foveal peak impairment on multifocal ERG, consistent with a toxic mechanism. Fluorescein and indocyanine green angiography performed at a distance does not show any ischemic or exudative phenomena. Ocular and systemic findings were not suggestive of a paraneoplastic process. Following discontinuation of carboplatin, anatomical and functional abnormalities stabilized. Carboplatin-induced toxic maculopathy is rare and may result in visual acuity loss. Multimodal imaging indicates involvement of foveal photoreceptor. The reversibility of structural and functional changes after treatment cessation remains uncertain. Given the uncertainty regarding both causality and the underlying mechanism, this case highlights the importance for oncologists and ophthalmologists to promptly evaluate any visual complaints arising during carboplatin therapy.